Jon Ebbert

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Varenicline for smoking cessation: efficacy, safety, and treatment recommendations
    Jon O Ebbert
    Mayo Clinic College of Medicine, Rochester, MN, USA
    Patient Prefer Adherence 4:355-62. 2010
  2. pmc Fat depots, free fatty acids, and dyslipidemia
    Jon O Ebbert
    Division of Primary Care Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Nutrients 5:498-508. 2013
  3. pmc Comparative effectiveness of the nicotine lozenge and tobacco-free snuff for smokeless tobacco reduction
    Jon O Ebbert
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Addict Behav 38:2140-5. 2013
  4. pmc A comparison of three smokeless tobacco dependence measures
    Jon O Ebbert
    Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Addict Behav 37:1271-7. 2012
  5. pmc Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals
    Edward J Mills
    Faculty of Health Sciences, University of Ottawa, Ottawa, Canada
    Tob Induc Dis 8:8. 2010
  6. pmc Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: a pilot randomized placebo-controlled trial
    Richard D Hurt
    Nicotine Dependence Center, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    J Negat Results Biomed 10:1. 2011
  7. ncbi request reprint Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users
    Jon O Ebbert
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Nicotine Tob Res 9:43-52. 2007
  8. pmc Nicotine percentage replacement among smokeless tobacco users with nicotine patch
    Jon O Ebbert
    Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA
    Drug Alcohol Depend 89:223-6. 2007
  9. pmc The Fagerström Test for Nicotine Dependence-Smokeless Tobacco (FTND-ST)
    Jon O Ebbert
    Nicotine Research Program, Primary Care Internal Medicine, Department of Internal Medicine, Mayo Clinic 200 1st Street Southwest, Rochester, MN 55905, USA
    Addict Behav 31:1716-21. 2006
  10. ncbi request reprint Predictors of smokeless tobacco initiation in a young adult military cohort
    Jon O Ebbert
    Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Am J Health Behav 30:103-12. 2006

Detail Information

Publications91

  1. pmc Varenicline for smoking cessation: efficacy, safety, and treatment recommendations
    Jon O Ebbert
    Mayo Clinic College of Medicine, Rochester, MN, USA
    Patient Prefer Adherence 4:355-62. 2010
    ....
  2. pmc Fat depots, free fatty acids, and dyslipidemia
    Jon O Ebbert
    Division of Primary Care Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Nutrients 5:498-508. 2013
    ..In the current review, we will explore the relationship between adipose tissue, body fat depots, and FFA metabolism...
  3. pmc Comparative effectiveness of the nicotine lozenge and tobacco-free snuff for smokeless tobacco reduction
    Jon O Ebbert
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Addict Behav 38:2140-5. 2013
    ..12%, one-tailed p=.615). The 4-mg nicotine lozenge and the tobacco-free snuff both appear to be effective and comparable for reducing ST use among ST users not ready to quit in the next 30 days...
  4. pmc A comparison of three smokeless tobacco dependence measures
    Jon O Ebbert
    Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Addict Behav 37:1271-7. 2012
    ..The use of the scales is discussed in terms of clinical usefulness and how each scale might assess differing aspects of tobacco dependence...
  5. pmc Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals
    Edward J Mills
    Faculty of Health Sciences, University of Ottawa, Ottawa, Canada
    Tob Induc Dis 8:8. 2010
    ..Although expectations of mild adverse effects have been observed to be independent predictors of reduced motivation to use NRT, adverse effects associated with NRT have not been precisely quantified...
  6. pmc Methylphenidate for treating tobacco dependence in non-attention deficit hyperactivity disorder smokers: a pilot randomized placebo-controlled trial
    Richard D Hurt
    Nicotine Dependence Center, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    J Negat Results Biomed 10:1. 2011
    ....
  7. ncbi request reprint Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users
    Jon O Ebbert
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Nicotine Tob Res 9:43-52. 2007
    ..High-dose nicotine patch therapy is safe and well tolerated in this population of tobacco users...
  8. pmc Nicotine percentage replacement among smokeless tobacco users with nicotine patch
    Jon O Ebbert
    Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA
    Drug Alcohol Depend 89:223-6. 2007
    ..We conclude that the use of 42 mg/day nicotine patch therapy is safe and should be considered as initial therapy in the clinical setting among ST users who use > or =3 cans/week...
  9. pmc The Fagerström Test for Nicotine Dependence-Smokeless Tobacco (FTND-ST)
    Jon O Ebbert
    Nicotine Research Program, Primary Care Internal Medicine, Department of Internal Medicine, Mayo Clinic 200 1st Street Southwest, Rochester, MN 55905, USA
    Addict Behav 31:1716-21. 2006
    ..Development and refinement of nicotine dependence measures for ST users are essential steps in order to advance the field of ST research...
  10. ncbi request reprint Predictors of smokeless tobacco initiation in a young adult military cohort
    Jon O Ebbert
    Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Am J Health Behav 30:103-12. 2006
    ..To identify predictors of smokeless tobacco (ST) initiation among young adults...
  11. pmc A pilot study of mailed nicotine lozenges with assisted self-help for the treatment of smokeless tobacco users
    Jon O Ebbert
    Mayo Clinic College of Medicine, 200 1st Street Southwest, Rochester, MN 55905, USA
    Addict Behav 35:522-5. 2010
    ..We conclude that the mailing of nicotine lozenges to ST users is a feasible and safe strategy the efficacy of which needs to be evaluated...
  12. ncbi request reprint Nicotine lozenges for the treatment of smokeless tobacco use
    Jon O Ebbert
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Nicotine Tob Res 9:233-40. 2007
    ..Future phase III clinical trials investigating the efficacy of nicotine lozenges are warranted...
  13. pmc The missing link in tobacco control
    Jon O Ebbert
    Nicotine Dependence Center, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    CMAJ 179:123-4. 2008
  14. pmc Predictors of smokeless tobacco abstinence
    Jon O Ebbert
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Am J Health Behav 32:735-40. 2008
    ..To investigate predictors of tobacco abstinence among smokeless tobacco (ST) users...
  15. ncbi request reprint Emerging drugs for the treatment of tobacco dependence
    Jon O Ebbert
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Expert Opin Emerg Drugs 14:23-32. 2009
    ..Tobacco use is a worldwide epidemic expected to cause 10 million annual deaths by 2020 globally. Newer pharmacotherapy increases the specificity of tobacco dependence treatment by affecting receptors mediating nicotine effects...
  16. doi request reprint Combination treatment with varenicline and nicotine replacement therapy
    Jon O Ebbert
    Mayo Clinic College of Medicine, 200 1st Street Southwest, Rochester, MN 55905, USA
    Nicotine Tob Res 11:572-6. 2009
    ..A paucity of data exists regarding the safety and effectiveness of combination treatment with varenicline and nicotine replacement therapy (NRT)...
  17. pmc Association between respiratory tract diseases and secondhand smoke exposure among never smoking flight attendants: a cross-sectional survey
    Jon O Ebbert
    Mayo Clinic College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Environ Health 6:28. 2007
    ..We undertook this study to evaluate the association between accumulated flight time in smoky airplane cabins and respiratory tract diseases in a cohort of never smoking flight attendants...
  18. ncbi request reprint Tobacco use quitline enrollment through dental practices: a pilot study
    Jon O Ebbert
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Am Dent Assoc 138:595-601. 2007
    ..Opportunities exist for dental providers to help patients who smoke by enrolling them in tobacco use quitlines. The authors conducted a pilot study to investigate whether such referrals were feasible and effective...
  19. pmc A randomized clinical trial of nicotine lozenge for smokeless tobacco use
    Jon O Ebbert
    Mayo Clinic College of Medicine Rochester, MN 55905, USA
    Nicotine Tob Res 11:1415-23. 2009
    ..Smokeless tobacco (ST) use is associated with adverse health consequences, and effective treatments are needed. Pilot data suggest that 4-mg nicotine lozenge decreases tobacco craving and nicotine withdrawal symptoms among ST users...
  20. ncbi request reprint Treating tobacco dependence: review of the best and latest treatment options
    Jon O Ebbert
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Thorac Oncol 2:249-56. 2007
    ..We review the currently available pharmacologic approaches to the treatment of tobacco dependence...
  21. doi request reprint Varenicline and bupropion sustained-release combination therapy for smoking cessation
    Jon O Ebbert
    Mayo Clinic College of Medicine, 200 1st Street Southwest, Rochester, MN 55905, USA
    Nicotine Tob Res 11:234-9. 2009
    ..Combination pharmacotherapy with these agents may increase long-term smoking abstinence rates above what is observed with single-agent therapy...
  22. pmc Combination pharmacotherapy for stopping smoking: what advantages does it offer?
    Jon O Ebbert
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Drugs 70:643-50. 2010
    ..Available data suggests that combination therapy may increase abstinence rates compared with monotherapy. However, the cost effectiveness of this approach has not been clearly demonstrated...
  23. pmc Smokeless tobacco reduction with the nicotine lozenge and behavioral intervention
    Jon O Ebbert
    Mayo Clinic, Rochester, MN 55905, USA
    Nicotine Tob Res 12:823-7. 2010
    ..Studies have evaluated smoking reduction with nicotine replacement therapy to reduce tobacco exposure and facilitate abstinence among cigarette smokers, but none have evaluated a reduction approach in smokeless tobacco (ST) users...
  24. pmc A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in Midwestern United States
    Jon O Ebbert
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Nicotine Tob Res 13:820-6. 2011
    ..We have conducted a pilot study to obtain preliminary evidence of efficacy of varenicline for the treatment of ST users in Midwestern United States...
  25. ncbi request reprint Searching the medical literature using PubMed: a tutorial
    Jon O Ebbert
    Division of Community Internal Medicine, Mayo Clinic, MN 55905, USA
    Mayo Clin Proc 78:87-91. 2003
    ..The purpose of this article is to assist clinicians in the development of the basic skills required to use PubMed to make informed clinical decisions...
  26. pmc Portion control for the treatment of obesity in the primary care setting
    Rebecca L Kesman
    Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA
    BMC Res Notes 4:346. 2011
    ..abstract:..
  27. doi request reprint Pharmacological interventions for the treatment of smokeless tobacco use
    Jon O Ebbert
    Mayo Clinic, Rochester, MN 55905, USA
    CNS Drugs 26:1-10. 2012
    ..Additional investigations of higher dose NRT and combination pharmacotherapy are needed to advance the treatment of SLT users...
  28. ncbi request reprint Treatments for spit tobacco use: a quantitative systematic review
    Jon O Ebbert
    Division of Community Internal Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Addiction 98:569-83. 2003
    ..Health-care providers have neither evidence summaries nor evidence-based guidelines to assist them in treating patients who use spit tobacco...
  29. pmc Evaluation of a student-run smoking cessation clinic for a medically underserved population
    Lindsay E Lough
    Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA
    BMC Res Notes 4:55. 2011
    ..abstract:..
  30. ncbi request reprint Cotinine as a biomarker of systemic nicotine exposure in spit tobacco users
    Jon O Ebbert
    Department of Internal Medicine, Division of Community Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Addict Behav 29:349-55. 2004
    ....
  31. ncbi request reprint Residential treatment for smokeless tobacco use: a case series
    Jon O Ebbert
    Nicotine Dependence Center, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    J Subst Abuse Treat 26:261-7. 2004
    ..More research is needed to replicate our findings and determine if comparable abstinence rates can be achieved with outpatient ST treatment programs using similar behavioral and pharmacotherapies...
  32. ncbi request reprint A survey of characteristics of smokeless tobacco users in a treatment program
    Jon O Ebbert
    Mayo Clinic of Medicine, Rochester, MN 55905, USA
    Am J Health Behav 29:25-35. 2005
    ..To determine the characteristics and outcomes of smokeless tobacco (ST) users receiving interventions in an outpatient tobacco-dependence treatment program...
  33. ncbi request reprint Smokeless tobacco: an emerging addiction
    Jon O Ebbert
    Department of Medicine, Mayo Clinic College of Medicine, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA
    Med Clin North Am 88:1593-605. 2004
    ..Clinical treatment of ST users requires an understanding of the unique characteristics of ST. This article reviews ST products, epidemiology, pharmacology, health risks, and treatment approaches...
  34. pmc The association of alcohol consumption with coronary heart disease mortality and cancer incidence varies by smoking history
    Jon O Ebbert
    Nicotine Research Center, Division of Community Internal Medicine, Rochester, MN 55905, USA
    J Gen Intern Med 20:14-20. 2005
    ..To evaluate the effect of alcohol on coronary heart disease (CHD), cancer incidence, and cancer mortality by smoking history...
  35. pmc Clinical utility of varenicline for smokers with medical and psychiatric comorbidity
    Jon O Ebbert
    Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Int J Chron Obstruct Pulmon Dis 4:421-30. 2009
    ..In conjunction with behavioral interventions and clinical monitoring for potential side effects, varenicline offers great hope for reducing smoking-attributable death and disability...
  36. pmc A pilot study to assess smokeless tobacco use reduction with varenicline
    Jon O Ebbert
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Nicotine Tob Res 12:1037-40. 2010
    ..Similarly, a reduction strategy may reduce ST exposure and increase ST abstinence rates among ST users not interested in quitting...
  37. pmc Bupropion SR for the treatment of smokeless tobacco use
    Lowell C Dale
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Drug Alcohol Depend 90:56-63. 2007
    ..We conducted a multicenter, randomized, double-blind, placebo-controlled, clinical trial to assess the efficacy and safety of bupropion SR for tobacco abstinence among ST users...
  38. doi request reprint Sibutramine for weight gain attenuation during smoking cessation with varenicline: a pilot study
    Amit Sood
    General Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Nicotine Tob Res 11:1479-84. 2009
    ..Varenicline is the most effective medication for smoking cessation but does not prevent weight gain. Combining sibutramine and varenicline may facilitate smoking abstinence if weight gain is attenuated...
  39. pmc No interaction of body mass index and smoking on diabetes mellitus risk in elderly women
    Michael W Cullen
    Nicotine Dependence Center, Primary Care Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Prev Med 48:74-8. 2009
    ..We sought to assess the interaction of smoking and body mass index (BMI) on diabetes risk...
  40. doi request reprint Gender differences in self-reported use, perceived efficacy, and interest in future use of nicotine-dependence treatments: A cross-sectional survey in adults at a tertiary care center for nicotine dependence
    Sujata Narayanan
    Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Gend Med 6:362-8. 2009
    ....
  41. doi request reprint Interventions for tobacco cessation in the dental setting
    Alan B Carr
    Department of Dental Specialities, Mayo Clinic, Rochester
    Cochrane Database Syst Rev 6:CD005084. 2012
    ..Tobacco use has significant adverse effects on oral health. Oral health professionals in the dental office or community setting have a unique opportunity to increase tobacco abstinence rates among tobacco users...
  42. pmc Feasibility of a telephone-based intervention for support persons to help smokers quit: a pilot study
    Christi A Patten
    Department of Psychiatry and Psychology and Behavioral Health Research Program, Mayo Clinic College of Medicine, Charlton 6 273, 200 First Street Southwest, Rochester, MN 55905, USA
    Nicotine Tob Res 11:427-32. 2009
    ..Nonsmokers have a potentially supportive role in tobacco cessation efforts. The present study examined the feasibility, acceptability, and potential efficacy of a telephone-based intervention for nonsmoking support persons...
  43. pmc "Efforts to Reprioritise the Agenda" in China: British American Tobacco's Efforts to Influence Public Policy on Secondhand Smoke in China
    Monique E Muggli
    Mayo Clinic, Rochester, Minnesota, USA
    PLoS Med 5:1729-69. 2008
    ..Internal tobacco industry documents show that transnational tobacco companies (TTCs) have pursued a multifaceted strategy for undermining the adoption of restrictions on smoking in many countries...
  44. pmc Open doorway to truth: legacy of the Minnesota tobacco trial
    Richard D Hurt
    Division of Primary Care Internal Medicine, Nicotine Dependence Center, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 84:446-56. 2009
    ....
  45. pmc Feasibility of an exercise counseling intervention for depressed women smokers
    Kristin S Vickers
    Department of Psychiatry and Psychology, Mayo Clinic Rochester, 200 First Street South West, Rochester, MN 55905, USA
    Nicotine Tob Res 11:985-95. 2009
    ..This pilot study investigated the feasibility of an exercise intervention for depressed female smokers (Center for Epidemiological Studies Depression Scale [CES-D] score > or =16)...
  46. pmc Treating tobacco dependence in light of the 2008 US Department of Health and Human Services clinical practice guideline
    J Taylor Hays
    Division of General Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 84:730-5; quiz 735-6. 2009
    ..This article briefly reviews the major updates and recommendations from the new guideline and highlights its practical clinical applications...
  47. doi request reprint Legislating tolerance: Spain's national public smoking law
    Monique E Muggli
    Mayo Clinic Nicotine Research Program, 127 Orlin Ave SE, Rochester, MN 55414, USA
    Tob Control 19:24-30. 2010
    ..In doing so, Spain's smoke-free public places law would be better aligned with the Framework Convention on Tobacco Control...
  48. doi request reprint The association of alcohol consumption with tobacco use in Black and White college students
    Steven C Ames
    Mayo Clinic, Jacksonville Florida, USA
    Subst Use Misuse 45:1230-44. 2010
    ..Racial and gender differences are highlighted. This study was funded by Mayo Clinic. The study's limitations were noted...
  49. pmc Residential treatment compared with outpatient treatment for tobacco use and dependence
    J Taylor Hays
    Nicotine Dependence Center, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 86:203-9. 2011
    ..To compare the effectiveness of outpatient vs residential treatment for tobacco dependence in a large referral practice...
  50. ncbi request reprint Cochrane systematic reviews in acupuncture: methodological diversity in database searching
    Amit Sood
    Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Altern Complement Med 11:719-22. 2005
    ..Results from these trials have been synthesized in systematic reviews. A well-designed systematic review provides the highest level of evidence for establishing the efficacy of a clinical intervention...
  51. pmc A randomized clinical trial of St. John's wort for smoking cessation
    Amit Sood
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Altern Complement Med 16:761-7. 2010
    ..St. John's wort (SJW) is a widely used herbal supplement. The predominant mechanism(s) accounting for the activity of SJW in vivo are, however, unclear. The purpose of this study was to investigate the efficacy of SJW for smoking cessation...
  52. doi request reprint Treating tobacco dependence in a medical setting
    Richard D Hurt
    Nicotine Dependence Center, Mayo Clinic, Rochester, MN 55905, USA
    CA Cancer J Clin 59:314-26. 2009
    ..The effective treatment of tobacco dependence frequently requires tailoring, and often intensifying, interventions (both counseling and pharmacotherapy) to meet the needs of the individual patient...
  53. ncbi request reprint The relationship between caffeine and blood pressure in preadolescent African American girls
    Jagadeshwar G Reddy
    Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Ethn Dis 18:283-8. 2008
    ..The primary objective of this study was to assess the cross-sectional relationship between caffeine intake and blood pressure in 8- to 10-year-old African American girls who eat an unrestricted diet...
  54. ncbi request reprint Preventing lung cancer by stopping smoking
    Richard D Hurt
    Nicotine Dependence Center, Division of Community Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Clin Chest Med 23:27-36, vii. 2002
    ..The use of these medications can be tailored to meet the patients needs and combinations of these medications can be used when appropriate. More intensive treatment, such as residential treatment, may be needed for more addicted smokers...
  55. ncbi request reprint Motivation for stopping tobacco use among emergency department patients
    Martin D Klinkhammer
    Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA
    Acad Emerg Med 12:568-71. 2005
    ....
  56. ncbi request reprint Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review
    Ping Yang
    Division of Epidemiology and Cancer Center, Nicotine Dependence Center, and Department of Molecular Pharmacology and Experimental Therapeutics, Rochester, MN 55905, USA
    J Clin Oncol 24:1761-9. 2006
    ..The potential application of glutathione system polymorphic genetic markers in identifying patients who may respond favorably, selecting effective antitumor drugs, and balancing drug efficacy and toxicity are discussed...
  57. ncbi request reprint Complementary treatments for tobacco cessation: a survey
    Amit Sood
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Nicotine Tob Res 8:767-71. 2006
    ..The high level of interest in CAM among tobacco users underscores the need to conduct further research in this field...
  58. ncbi request reprint Clinicians' guide to new tools and features of PubMed
    Denise M Dupras
    Division of Primary Care Internal Medicine, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:480-3; quiz 484. 2007
    ..This article is the third in a Mayo Clinic Proceedings series designed specifically to help clinicians unlock the tools and information available through this valuable resource...
  59. pmc Survey assessment of personal digital assistant use among trainees and attending physicians
    Thomas G McLeod
    Division of Community Internal Medicine, Department of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    J Am Med Inform Assoc 10:605-7. 2003
    ..These findings may reflect differences in the information needs and work roles of learners and experienced physicians. Such factors may be important considerations for the development and implementation of institutional PDA resources...
  60. ncbi request reprint Bupropion sustained release for treatment of tobacco dependence
    J Taylor Hays
    Division of General Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:1020-4; quiz 1024. 2003
    ....
  61. ncbi request reprint Development of a telephone-based intervention for support persons to help smokers quit
    Christi A Patten
    Department of Psychiatry and Psychology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55901, USA
    Psychol Health Med 13:17-28. 2008
    ..Results indicate that the telephone-based intervention was feasible and acceptable to participants. The intervention was refined based on participant and counselor feedback and will be subsequently tested in a randomized pilot trial...
  62. ncbi request reprint Bupropion for the treatment of tobacco dependence: guidelines for balancing risks and benefits
    J Taylor Hays
    Mayo Nicotine Dependence Center, Rochester, Minnesota 55905, USA
    CNS Drugs 17:71-83. 2003
    ..Recent postmarketing surveillance reports have raised safety concerns about bupropion, although no causal relationship between bupropion and the reported serious adverse events or death has been established...
  63. ncbi request reprint Differences among Black and White young adults on prior attempts and motivation to help a smoker quit
    Christi A Patten
    Department of Psychiatry and Psychology and Behavioral Health Research Program, Mayo Clinic Rochester, Rochester, MN 55901, United States
    Addict Behav 33:496-502. 2008
    ..Tobacco control efforts could focus on optimizing these supportive behaviors as well as expressed motivation and interest in helping a smoker to quit among young adult nonsmokers...
  64. doi request reprint Clinical consequences of withholding versus administering renin-angiotensin-aldosterone system antagonists in the preoperative period
    David J Rosenman
    Knowledge and Encounter Research Unit, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Hosp Med 3:319-25. 2008
    ..This practice variation reflects uncertainty regarding the risks and benefits of either approach...
  65. pmc Waking a sleeping giant: the tobacco industry's response to the polonium-210 issue
    Monique E Muggli
    Nicotine Research Program, Mayo Clinic, Rochester, MN 55905, USA
    Am J Public Health 98:1643-50. 2008
    ..Tobacco companies continue to minimize their knowledge about polonium-210 in cigarettes in smoking and health litigation. Cigarette packs should carry a radiation-exposure warning label...
  66. ncbi request reprint Simultaneous analysis of nicotine, nicotine metabolites, and tobacco alkaloids in serum or urine by tandem mass spectrometry, with clinically relevant metabolic profiles
    Thomas P Moyer
    Drug Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA
    Clin Chem 48:1460-71. 2002
    ..Absence of nicotine metabolites and anabasine can be used to document abstinence from tobacco products, an indicator of treatment success...
  67. ncbi request reprint Bupropion for the treatment of nicotine dependence in spit tobacco users: a pilot study
    Lowell C Dale
    Division of Community Internal Medicine, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Nicotine Tob Res 4:267-74. 2002
    ..2 +/- 5.0 kg in the placebo group (p = 0.49). Bupropion may increase abstinence rates in ST users and appears to attenuate weight gain during ST abstinence. Larger randomized, controlled trials of bupropion for ST users are needed...
  68. doi request reprint Efficacy and safety of varenicline for smoking cessation
    J Taylor Hays
    Nicotine Dependence Center, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Med 121:S32-42. 2008
    ..As the newest agent approved for smoking cessation, the mechanism of action, efficacy, and safety of varenicline...
  69. ncbi request reprint Gabapentin for smoking cessation: a preliminary investigation of efficacy
    Amit Sood
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Nicotine Tob Res 9:291-8. 2007
    ..Our results suggest that gabapentin may increase smoking abstinence. An adequately powered randomized clinical trial assessing different doses of this drug against a placebo would be the reasonable next step...
  70. ncbi request reprint Iqmik--a form of smokeless tobacco used by pregnant Alaska natives: nicotine exposure in their neonates
    Richard D Hurt
    Nicotine Dependence Center, Mayo Clinic, Rochester, MN 55905, USA
    J Matern Fetal Neonatal Med 17:281-9. 2005
    ..To determine the concentration of nicotine and cotinine in maternal blood and neonatal cord blood among pregnant Alaska Native women and to assess the neonates for neurobehavioral effects...
  71. doi request reprint Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers: an open-label pilot study
    J Taylor Hays
    Mayo Clinic, Nicotine Dependence Center, Rochester, Minnesota 55905, USA
    J Subst Abuse Treat 40:102-7. 2011
    ..No serious adverse events were reported. Varenicline may be a useful aid for treating tobacco dependence among smokers who are in stable recovery from alcohol dependence. Further study of this treatment is warranted...
  72. doi request reprint Gender differences among smokers receiving interventions for tobacco dependence in a medical setting
    Ivana T Croghan
    Mayo Clinic, Nicotine Dependence Center, 200 First St, SW, Rochester, Minnesota 55905, United States
    Addict Behav 34:61-7. 2009
    ..The purpose of this study was to assess differences between women and men receiving treatment for tobacco dependence through a clinical treatment program...
  73. doi request reprint Adverse effects and tolerability of medications for the treatment of tobacco use and dependence
    J Taylor Hays
    Mayo Clinic Nicotine Dependence Center, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Drugs 70:2357-72. 2010
    ..Given these factors, the benefit : risk ratio is strongly in favour of pharmacotherapy for tobacco dependence treatment in virtually all smokers who are motivated to quit...
  74. ncbi request reprint Interventions for smokeless tobacco use cessation
    Jon Ebbert
    Department of Primary Care Internal Medicine, Mayo Clinic, 200 1st Street Southwest, Rochester, Minnesota, USA, 55905
    Cochrane Database Syst Rev 2:CD004306. 2011
    ..Use of smokeless tobacco (ST) can lead to nicotine addiction and long-term use can lead to health problems including periodontal disease, cancer, and cerebrovascular and cardiovascular disease...
  75. pmc Zebrafish for the study of the biological effects of nicotine
    Eric W Klee
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
    Nicotine Tob Res 13:301-12. 2011
    ..When combined with a battery of molecular-genetic tools and behavioral assays, these attributes enable studies to be conducted that are not practical using traditional animal models...
  76. ncbi request reprint Tobacco use outcomes among patients with lung cancer treated for nicotine dependence
    Lisa Sanderson Cox
    Nicotine Research Center, Department of Psychiatry and Psychology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Clin Oncol 20:3461-9. 2002
    ..This retrospective study examined the 6-month tobacco abstinence rate among lung cancer patients treated clinically for nicotine dependence...
  77. doi request reprint Smokeless tobacco reduction: preliminary study of tobacco-free snuff versus no snuff
    Dorothy K Hatsukami
    University of Minnesota, Tobacco Use Research Center, Minneapolis, MN 55414, USA
    Nicotine Tob Res 10:77-85. 2008
    ....
  78. doi request reprint Treatment of tobacco dependence
    Michael V Burke
    Nicotine Dependence Center, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:479-83; quiz 483-4. 2008
    ..Because tobacco dependence is characterized by relapses and remissions, clinicians should be ready to engage smokers and reengage relapsed smokers with options for new medication strategies and additional counseling resources...
  79. ncbi request reprint Changing smokeless tobacco products new tobacco-delivery systems
    Dorothy K Hatsukami
    Transdisciplinary Tobacco Use Research Center, University of Minnesota, Minneapolis, Minnesota 55414, USA
    Am J Prev Med 33:S368-78. 2007
    ....
  80. ncbi request reprint A multidimensional workshop using human cadavers to teach bedside procedures
    Amy S Oxentenko
    Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Teach Learn Med 15:127-30. 2003
    ..Internal medicine residents should be able to perform bedside procedures safely and efficiently...
  81. ncbi request reprint Trial design: blood pressure control and weight gain prevention in prehypertensive and hypertensive smokers: the treatment and prevention study
    Mark W Vander Weg
    Iowa City VA Medical Center, Center for Research in the Implementation of Innovative Strategies in Practice CRIISP, University of Iowa Dept of Internal Medicine, Iowa City, IA 52246, USA
    Contemp Clin Trials 29:281-92. 2008
    ..Intervention strategies that facilitate smoking cessation and modify adverse changes in body weight and BP are needed...
  82. ncbi request reprint Iqmik: a form of smokeless tobacco used among Alaska natives
    Caroline C Renner
    Office of Alaska Native Health Research, Alaska Native Tribal Health Consortium, Anchorage, AK 99508, USA
    Am J Health Behav 29:588-94. 2005
    ..To describe a homemade form of smokeless tobacco known as Iqmik used among Alaska Natives residing in western Alaska...
  83. pmc Prevalence of alternative forms of tobacco use in a population of young adult military recruits
    Mark W Vander Weg
    Center for Research in the Implementation of Innovative Strategies in Practice CRIISP, VA Medical Center, 601 Highway 6 West, Mail Stop 152, Iowa City, IA 52246, United States
    Addict Behav 33:69-82. 2008
    ..001). Patterns of use also differed according to other demographic characteristics including race, ethnicity, age, and income. Implications for surveillance and tobacco control efforts are discussed...
  84. ncbi request reprint Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality
    Aditya Bardia
    Department of Internal Medicine, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    J Natl Cancer Inst 99:881-9. 2007
    ..We evaluated associations between aspirin and nonaspirin NSAID use with cancer incidence and mortality stratified by smoking history in the Iowa Women's Health Study, a prospective cohort of postmenopausal women...
  85. ncbi request reprint Measuring nicotine dependence among smokeless tobacco users
    Janet L Thomas
    University of Kansas Medical Center, Department of Preventive Medicine and Public Health, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA
    Addict Behav 31:1511-21. 2006
    ..493+/-246 ng/ml; P=0.042). Poor concordance was observed between the FTQ-ST and the DIS-IV in the assessment of nicotine dependence in ST users...
  86. ncbi request reprint Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk
    Ping Yang
    Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Chest 128:445-52. 2005
    ..We conducted a case-control study to investigate whether genetic variations indicative of alpha(1)-antitrypsin deficiency (A1ATD) or an excess of neutrophil elastase modify lung cancer risk..
  87. ncbi request reprint Re: chronic disease mortality in a cohort of smokeless tobacco users
    Jon O Ebbert
    Am J Epidemiol 158:1021; author reply 1021-2. 2003
  88. ncbi request reprint Using advanced search tools on PubMed for citation retrieval
    Amit Sood
    Division of General Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:1295-9; quiz 1300. 2004
    ..In this article, we build on this foundation and present advanced search tools designed to assist clinicians in performing efficient and focused literature searches...
  89. ncbi request reprint Methylprednisolone, valacyclovir, or both for vestibular neuritis
    Amit Sood
    N Engl J Med 351:2344-5; author reply 2344-5. 2004
  90. ncbi request reprint The relationship between cigarette smoking and quality of life after lung cancer diagnosis
    Yolanda I Garces
    Mayo Clinic, Charlton 6, 200 First Street SW, Rochester, MN 55905, USA
    Chest 126:1733-41. 2004
    ..To describe the relationship between cigarette smoking and quality of life (QOL) among lung cancer survivors as measured by the lung cancer symptom scale (LCSS)...
  91. ncbi request reprint A qualitative assessment of 1st-year internal medicine residents' perceptions of evidence-based clinical decision making
    Victor M Montori
    Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Teach Learn Med 14:114-8. 2002
    ..Residents' perceptions about evidence-based clinical decision making remain largely unexplored...

Research Grants10

  1. Evaluating Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
    Jon Ebbert; Fiscal Year: 2009
    ..No drug therapies have been shown to be effective for helping smokeless tobacco users quit for good. The purpose of this study is to test drugs that can be used to help smokeless tobacco users quit for good. ..
  2. High Dose Nicotine Patch Therapy for Spit Tobacco Users
    Jon Ebbert; Fiscal Year: 2004
    ..Our goal is to reduce the prevalence of ST use and decrease the incidence of oropharyngeal cancer through the development of effective treatment options for ST users. ..
  3. Brief Dental Office Intervention with Tobacco Quitline
    Jon Ebbert; Fiscal Year: 2005
    ..S. adult population smoking; and 3) 75% of smokers quitting for at least one day or longer because they are trying to quit. ..
  4. Evaluating Nicoting Lozenges for Treatment of Smokeless Tobacco Addiction
    Jon Ebbert; Fiscal Year: 2007
    ..No drug therapies have been shown to be effective for helping smokeless tobacco users quit for good. The purpose of this study is to test drugs that can be used to help smokeless tobacco users quit for good. ..
  5. Combination Therapy with Varenicline and Bupropion for Smoking Cessation
    Jon O Ebbert; Fiscal Year: 2010
    ..Combining medications together may increase the long-term smoking quit rates and decrease the death and disability associated with cigarette smoking. ..